Pfizer Expected to Post Q1 2018 Earnings of $0.73 Per Share (PFE)

Pfizer (NYSE:PFE) – Investment analysts at Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for Pfizer in a research note issued to investors on Friday, April 13th. Jefferies Group analyst I. Hilliker forecasts that the biopharmaceutical company will post earnings of $0.73 per share for the quarter. Jefferies Group currently has a “Hold” rating and a $38.00 price objective on the stock. Jefferies Group also issued estimates for Pfizer’s FY2020 earnings at $3.18 EPS, FY2021 earnings at $3.49 EPS and FY2022 earnings at $3.89 EPS.

How to Become a New Pot Stock Millionaire

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The business had revenue of $13.70 billion for the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter last year, the company earned $0.47 EPS. The company’s revenue for the quarter was up .6% compared to the same quarter last year.

A number of other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, April 12th. Citigroup restated a “sell” rating on shares of Pfizer in a research report on Thursday, April 12th. Berenberg Bank reiterated a “neutral” rating and issued a $37.00 target price on shares of Pfizer in a report on Wednesday, April 11th. Barclays cut shares of Pfizer from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $41.00 to $38.00 in a report on Thursday, April 5th. Finally, BMO Capital Markets set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, April 2nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $39.20.

PFE stock opened at $36.53 on Monday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. Pfizer has a fifty-two week low of $31.67 and a fifty-two week high of $39.43. The stock has a market capitalization of $216,208.05, a P/E ratio of 13.78, a PEG ratio of 1.82 and a beta of 0.90.

Pfizer declared that its Board of Directors has initiated a share buyback program on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its stock is undervalued.

In related news, Director W Don Cornwell sold 1,758 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total transaction of $64,676.82. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at $36,790. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Sally Susman sold 33,368 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $37.03, for a total transaction of $1,235,617.04. Following the transaction, the executive vice president now directly owns 191,505 shares in the company, valued at approximately $7,091,430.15. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 248,037 shares of company stock worth $9,064,785. Insiders own 0.06% of the company’s stock.

Several large investors have recently added to or reduced their stakes in PFE. Earnest Partners LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $105,000. First Dallas Securities Inc. bought a new position in shares of Pfizer in the fourth quarter valued at approximately $118,000. Woodard & Co. Asset Management Group Inc. ADV bought a new position in shares of Pfizer in the fourth quarter valued at approximately $118,000. Delpha Capital Management LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $126,000. Finally, Americafirst Capital Management LLC bought a new position in Pfizer during the third quarter worth $127,000. 71.19% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Pfizer Expected to Post Q1 2018 Earnings of $0.73 Per Share (PFE)” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2018/04/17/pfizer-expected-to-post-q1-2018-earnings-of-0-73-per-share-pfe.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply